In December 2023, the U.S. Food and Drug Administration approved Casgevy — the world’s first CRISPR-based medicine cleared for human use. It treats sickle cell disease, a painful and life-shortening genetic disorder that affects roughly 100,000 Americans, most of whom are of African descent.

This is not just a medical milestone. It is the moment a technology once confined to laboratory petri dishes crossed into actual human bodies and rewrote the rules of what “treatment” means. To understand why this is so significant, we first need to understand the disease it targets — and the microscopic scissors that fix it.

What Is Sickle Cell Disease?

Your red blood cells are supposed to be round and flexible — like soft donuts that can squeeze through the narrowest capillaries in your body. In sickle cell disease, a single mutation in the HBB gene causes hemoglobin (the protein that carries oxygen) to behave abnormally under low-oxygen conditions.

Instead of staying dissolved and functional, mutated hemoglobin molecules clump together and form long, rigid rods. These rods distort the red blood cell into a crescent — a “sickle” shape. Sickled cells are stiff, sticky, and short-lived. They clog blood vessels, starve organs of oxygen, and cause episodes of excruciating pain called vaso-occlusive crises.

Because sickle cell disease is autosomal recessive, a person must inherit two copies of the mutated gene — one from each parent — to develop the full disease. Carriers (one copy) generally live normal lives. This inheritance pattern is key to understanding why CRISPR offers such a clean solution.

Enter CRISPR: Molecular Scissors That Read DNA

CRISPR-Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats — a mouthful that describes a natural immune system bacteria evolved to fight viruses. Scientists discovered they could repurpose this system as a precise gene-editing tool.

Here is the simplest way to understand it: CRISPR is a two-part system consisting of a guide RNA (a short piece of RNA designed to find a specific DNA sequence) and the Cas9 protein (an enzyme that acts as scissors). The guide RNA leads Cas9 to an exact location in the genome, and Cas9 makes a cut.

How Casgevy Actually Works — Step by Step

Casgevy does not directly fix the broken HBB gene. Instead, it uses a clever biological workaround rooted in our own developmental history.

What Do the Results Actually Show?

In clinical trials, the results were remarkable. Of the 29 patients treated with Casgevy and followed for at least 12 months, 28 — more than 96% — were completely free of severe vaso-occlusive pain crises for at least a year after treatment. Many showed a dramatic increase in fetal hemoglobin levels, often exceeding 40% of their total hemoglobin (normal adults have less than 1%).

A second CRISPR therapy approved the same day — Lyfgenia, made by bluebird bio — takes a different approach, directly inserting a functional copy of the hemoglobin gene. Both therapies represent a one-time, potentially permanent treatment.

The Bigger Picture: What This Means for Biology

Sickle cell disease is just the beginning. CRISPR-based therapies are now in clinical trials for dozens of conditions, including beta-thalassemia, certain forms of blindness, HIV, and multiple cancers. The FDA approval of Casgevy signals that the regulatory and safety framework for these therapies is maturing.

There are still significant challenges. The current treatment process is grueling and expensive — Casgevy is priced at approximately $2.2 million per patient. It also requires destroying existing bone marrow with chemotherapy before the edited cells are infused, which carries its own risks. Access remains deeply unequal.

But the biological proof-of-concept is now undeniable. We can take a cell out of a human body, rewrite a specific instruction in its DNA with molecular-level precision, put the cell back, and have it function correctly — possibly for the rest of that person’s life. That is one of the most profound demonstrations of applied biology in history.